Back to top

Analyst Blog

Citi Venture Capital International (CVCI) – a private equity wing of Citigroup, Inc. (C - Analyst Report) – is expected to make an investment of $72.1 million (INR 400 crores) in India-based Sree Jayajothi Cements, The Times of India reported on Monday. Sree Jayajothi Cements – a diversified unit of Shriram Group – has a plant in the Kurnool-Kadappa region of Andhra Pradesh with a production capacity of 3.2 million tons per annum.

With the ongoing concerns among global buyout firms about investing in India as returns have gone down due to rupee depreciation, the prospects of the Indian cement sector is on the verge of a downtrend. Some movements in the sector are visible, as recently Irish giant CRH and Aditya Birla have shown interest in purchasing the Gujarat plants of Jaypee Cements.

Among other private equity firms, The Blackstone Group LP (BX - Analyst Report), Kohlberg Kravis Roberts & Co. (KKR - Snapshot Report) and Mount Kellet were in talks about investing in Jayajothi. For converting its loans into equity, Shriram Group acquired a 70% stake in Jayajothi earlier in 2012.

With Jayajothi having large debts and ongoing regulatory intrusions in the cement sector, a definite deal is long awaited. Shriram Group aims to get a financial partner for the revival of the cement unit. Moreover, it plans to bestow equal stake post-dilution to the new investor.

Moreover, Chennai-based Shriram Group had valued Jayajothi at approximately $85-90 per ton when loans into equity were converted, and therefore anticipates same valuation for new investors.

CVCI is a private equity firm, specializing in restructuring and industry consolidations in emerging markets. It focuses on private equity groups which make investments for entrepreneurs and business families. CVCI recently invested INR 764 crore in Mumbai-based Cox & Kings. The company is looking for the best investment opportunities in India to increase profitability.

Recently, the private equity arm of The Goldman Sachs Group Inc. (GS - Analyst Report) and New Enterprise Associates (NEA), an American venture capital fund, came together with an investment of $54 million in Bangalore-based Nova Medical Centers. Nova is a leading Indian healthcare firm for day/short-stay surgical care and fertility.

Citigroup currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. Considering the fundamentals, we also maintain our Neutral recommendation on the stock.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%